<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>44(1)</volume><submitter>He YF</submitter><pubmed_abstract>TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [&lt;sup>14&lt;/sup>C]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 μCi) of [&lt;sup>14&lt;/sup>C]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (T&lt;sub>max&lt;/sub>) of 0.667 h and a half-life (t&lt;sub>1/2&lt;/sub>) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collecte</pubmed_abstract><journal>Acta pharmacologica Sinica</journal><pagination>221-233</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9813128</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pharmacokinetics, mass balance, and metabolism of [&lt;sup>14&lt;/sup>C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension.</pubmed_title><pmcid>PMC9813128</pmcid><pubmed_authors>Yu CY</pubmed_authors><pubmed_authors>Yang FP</pubmed_authors><pubmed_authors>Yao XM</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Liu YM</pubmed_authors><pubmed_authors>Duan HQ</pubmed_authors><pubmed_authors>Diao XX</pubmed_authors><pubmed_authors>He YF</pubmed_authors><pubmed_authors>Yu C</pubmed_authors><pubmed_authors>Shen JS</pubmed_authors><pubmed_authors>Liu GY</pubmed_authors><pubmed_authors>Yu JH</pubmed_authors><pubmed_authors>Cheng H</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Odilov A</pubmed_authors><pubmed_authors>Tian GH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmacokinetics, mass balance, and metabolism of [&lt;sup>14&lt;/sup>C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension.</name><description>TPN171 is a novel phosphodiesterase-5 (PDE5) inhibitor used to treat pulmonary arterial hypertension (PAH) and erectile dysfunction (ED), which currently is undergoing phase II clinical trials in China. In this single-center, single-dose, nonrandomized, and open design study, radiolabeled [&lt;sup>14&lt;/sup>C]TPN171 was used to investigate the metabolic mechanism, pharmacokinetic characteristics, and clearance pathways of TPN171 in 6 healthy Chinese male volunteers. Each volunteer was administered a single oral suspension of 10 mg (100 μCi) of [&lt;sup>14&lt;/sup>C]TPN171. We found that TPN171 was absorbed rapidly in humans with a peak time (T&lt;sub>max&lt;/sub>) of 0.667 h and a half-life (t&lt;sub>1/2&lt;/sub>) of approximately 9.89 h in plasma. Excretion of radiopharmaceutical-related components was collecte</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-04-29T02:25:25.025Z</modification><creation>2025-04-20T09:26:30.522Z</creation></dates><accession>S-EPMC9813128</accession><cross_references><pubmed>35676531</pubmed><doi>10.1038/s41401-022-00922-6</doi></cross_references></HashMap>